Brainstorm Cell Therapeutics Inc. (BCLI) Clearly Signals Buy-Into the Stock: Don’t ignore the signals

Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) stock fell -9.74% on Wednesday to $1.76 against a previous-day closing price of $1.95. With 0.3 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.27 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.9899 whereas the lowest price it dropped to was $1.7500. The 52-week range on BCLI shows that it touched its highest point at $4.70 and its lowest point at $1.09 during that stretch. It currently has a 1-year price target of $7.00. Beta for the stock currently stands at -0.34.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BCLI was up-trending over the past week, with a rise of 4.76%, but this was down by -50.35% over a month. Three-month performance dropped to -55.56% while six-month performance fell -39.31%. The stock lost -40.74% in the past year, while it has lost -56.00% so far this year. A look at the trailing 12-month EPS for BCLI yields -0.70 with Next year EPS estimates of -0.58. For the next quarter, that number is -0.14. This implies an EPS growth rate of 36.60% for this year and 13.40% for next year.

Float and Shares Shorts:

At present, 36.49 million BCLI shares are outstanding with a float of 28.31 million shares on hand for trading. On Oct 13, 2022, short shares totaled 2.44 million, which was 6.68% higher than short shares on Sep 14, 2022. In addition to Mr. Chaim Lebovits as the firm’s Chief Exec. Officer, Dr. Irit Arbel DSc, Ph.D. serves as its Co-Founder & Independent Vice Chair of the Board.

Institutional Ownership:

Through their ownership of 10.98% of BCLI’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 5.63% of BCLI, in contrast to 5.04% held by mutual funds. Shares owned by individuals account for 14.48%. As the largest shareholder in BCLI with 3.87% of the stake, The Vanguard Group, Inc. holds 1,413,042 shares worth 1,413,042. A second-largest stockholder of BCLI, BlackRock Fund Advisors, holds 459,726 shares, controlling over 1.26% of the firm’s shares. Abner, Herrman & Brock LLC is the third largest shareholder in BCLI, holding 280,000 shares or 0.77% stake. With a 2.61% stake in BCLI, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 951,371 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 1.11% of BCLI stock, is the second-largest Mutual Fund holder. It holds 405,606 shares valued at 1.44 million. JPMorgan Funds – Thematics – Gene holds 0.51% of the stake in BCLI, owning 187,070 shares worth 0.67 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BCLI since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With BCLI analysts setting a high price target of $21.00 and a low target of $5.00, the average target price over the next 12 months is $13.00. Based on these targets, BCLI could surge 1093.18% to reach the target high and rise by 184.09% to reach the target low. Reaching the average price target will result in a growth of 638.64% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. BCLI will report FY 2022 earnings on 03/29/2023. Analysts have provided yearly estimates in a range of -$0.63 being high and -$0.72 being low. For BCLI, this leads to a yearly average estimate of -$0.68. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Brainstorm Cell Therapeutics Inc. surprised analysts by -$0.01 when it reported -$0.19 EPS against a consensus estimate of -$0.18. The surprise factor in the prior quarter was -$0.04. Based on analyst estimates, the high estimate for the next quarter is -$0.11 and the low estimate is -$0.18. The average estimate for the next quarter is thus -$0.14.

Summary of Insider Activity:

Insiders traded BCLI stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 12 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 147,719 while 0 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

Receive Best Stock To Trade Before The Opening Bell



100% Free. Stop Anytime. No Spam